Immunis Initiates Patient Enrollment for Muscle Atrophy Phase 1/2a Clinical Trial

IRVINE, Calif.–(BUSINESS WIRE)– #ClinicalTrials–Immunis, a biotech company creating a novel treatment for disease-related immune decline, initiates patient enrollment for Phase 1/2a clinical trials.